Beta1 integrin expression in malignant melanoma predicts occult lymph node metastases

Tina J. Hieken, Salve G. Ronan, Miguel Farolan, Anne L. Shilkaitis, Dong K. Kim, Tapas K. Das Gupta

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Background Elective lymph node dissection for malignant melanoma is still controversial. Experimental studies suggest that differential expression, activation, or both of β1 integrins facilitate melanoma metastases. However, the clinical significance of β1 integrin expression in human melanoma is unclear. Methods We examined primary cutaneous melanomas from 76 patients undergoing elective lymph node dissection. We quantified the percentage of tumor area stained by β1 integrin antibody with an image analyzer. Results β1 integrin was expressed in all 23 primary tumors from patients with pathologically positive lymph nodes (LNs) but in only 14 (26%) of 53 cases with pathologically negative nodes (p<0.001). No patients with β1 integrin-negative tumors had LN involvement, whereas 23 (62%) of 37 patients with β1 integrin-positive tumors had LN metastases (p<0.001). Furthermore, 21 (91%) of 23 cases with LN metastases but only 4 (8%) of 53 cases without had β1 integrin staining of 10% or more of tumor area (p<0.001). Conclusions Our study is the first to show a correlation between expression of a molecular marker in the primary cutaneous melanoma and likelihood of regional LN metastases. β1 immunostaining of 10% or more of tumor area reliably predicts patients most likely to harbor occult LN metastases and likely to benefit from ELND.

Original languageEnglish (US)
Pages (from-to)669-675
Number of pages7
Issue number4
StatePublished - Oct 1995

ASJC Scopus subject areas

  • Surgery


Dive into the research topics of 'Beta1 integrin expression in malignant melanoma predicts occult lymph node metastases'. Together they form a unique fingerprint.

Cite this